-Saving Drug
April 22, 2023
Trending News ☀️
Intellia Therapeutics ($NASDAQ:NTLA) has emerged as a promising player in the field of drug discovery, providing new hope for those in need of treatments for serious illnesses. By harnessing the power of gene editing, Intellia Therapeutics has pioneered novel approaches to drug discovery, showing signs of possible life-saving treatments on the horizon. Intellia Therapeutics has made groundbreaking progress in the development of its therapies and is continuing to make advances in the field. Through its innovative research, the company has created a pipeline of therapeutic candidates that are being tested in pre-clinical and clinical trials.
In addition to its cutting-edge technology and research efforts, Intellia Therapeutics has also become an attractive investment opportunity. The company’s stock has performed strongly in recent years, and investors have faith in its potential to make a real difference in the lives of patients. With its incredible progress and potential life-saving treatments, Intellia Therapeutics is paving the way for new hope.
Stock Price
Friday was a good day for Intellia Therapeutics Inc. as their stock opened at $35.9 and closed at $37.1, a 3.9% increase from the last closing price of $35.8. This showed the market’s confidence in Intellia’s promising drug discovery and its potential to save lives. This technology has been used to develop a new gene-editing therapy that has the potential to cure diseases caused by gene mutations. In order to make a lasting impact, Intellia is focusing on producing medicine that not only treats diseases, but also has the ability to prevent them by editing mutated genes. With this breakthrough in gene therapy, Intellia is paving the way for a new hope in medical research and drug discovery.
Intellia’s drug will be a revolutionary addition to the medical field, and its potential to save lives is undeniable. This is the motivation that drove the market to give Intellia Therapeutics a 3.9% boost in stock price. Intellia Therapeutics is showing the world what is possible with gene therapy and drug discovery. With this breakthrough, Intellia is providing a new hope for those suffering from terminal illnesses, helping them to lead healthier and longer lives. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Intellia Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 52.12 | -474.19 | -883.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Intellia Therapeutics. More…
| Operations | Investing | Financing |
| -333.29 | 160.31 | 582.96 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Intellia Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.52k | 284.53 | 14.19 |
Key Ratios Snapshot
Some of the financial key ratios for Intellia Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 6.5% | – | -879.0% |
| FCF Margin | ROE | ROA |
| -751.5% | -27.8% | -18.8% |
Analysis
At GoodWhale, we have conducted a detailed analysis of INTELLIA THERAPEUTICS‘ fundamentals. Our Star Chart shows that INTELLIA THERAPEUTICS is classified as the ‘cheetah’- a type of company that has achieved high revenue and earnings growth, but may be considered less stable due to lower profitability. Investors who are willing to take on higher risk in order to potentially achieve higher returns may be interested in investing in INTELLIA THERAPEUTICS. We find that INTELLIA THERAPEUTICS has an intermediate health score of 4/10 with regard to its cashflows and debt position, meaning that it might be able to pay off debt and fund future operations. Further, we identify that INTELLIA THERAPEUTICS is strong in assets, growth and weak in dividends and profitability. More…
Peers
The company was founded in 2014 and is based in Cambridge, Massachusetts. Intellia has developed a platform that can be used to edit genes in a variety of cells and tissues. The company is also working on developing CRISPR-based treatments for diseases such as cancer and HIV. Intellia’s main competitors are CRISPR Therapeutics AG, Regeneron Pharmaceuticals Inc, and Editas Medicine Inc.
– CRISPR Therapeutics AG ($NASDAQ:CRSP)
Crispr Therapeutics AG is a biopharmaceutical company that focuses on the development of CRISPR/Cas9-based therapeutics for serious diseases. The company’s market cap as of 2022 is 4.28B and its ROE is -18.27%. Crispr Therapeutics AG was founded in 2013 and is headquartered in Zug, Switzerland.
– Regeneron Pharmaceuticals Inc ($NASDAQ:REGN)
Regeneron Pharmaceuticals Inc is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company’s products include EYLEA, Praluent, Dupixent, Libtayo, and Kevzara. As of 2021, the company had a market cap of $80.72 billion and a return on equity of 19.7%. Regeneron was founded in 1988 and is headquartered in Tarrytown, New York.
– Editas Medicine Inc ($NASDAQ:EDIT)
Editas Medicine Inc is a genome editing company based in Cambridge, Massachusetts. The company uses a technology called CRISPR to edit genes in order to treat genetic diseases. As of 2022, Editas Medicine Inc has a market cap of 886.02M and a Return on Equity of -23.75%. The company’s focus on genome editing makes it a leader in the field, and its market cap and ROE reflect this.
Summary
With a strong pipeline of products in development, Intellia Therapeutics has the potential to generate significant value for investors in the long term.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
